DalsnaFinance

Omniab Inc $OABI

Health Care

Russell 2000 California
Create a scorecard
$4.76
-0.15 (-3.05%)
As of Oct 22, 2026, 3:57 PM EDT · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 7, 2026, the first target we tracked for OABI.

Omniab Inc (OABI) is trading down at $4.76 (-3.05%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

Analyst price targets on OABI

One firm's current price target on Omniab Inc: $6 — 26% above the current $4.76. Each is tracked to its date and scored the same way a member's call is.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Omniab Inc revenue & net income history (FY2021–FY2025)

RevenueNet incomeNet margin (right axis, %)
$59.1M−$2.85M−$64.8MFY2021 revenue: $34.7MFY2021 net income: −$27.0M · Net margin −77.8%'21FY2022 revenue: $59.1MFY2022 net income: −$22.3M · Net margin −37.8%'22FY2023 revenue: $34.2MFY2023 net income: −$50.6M · Net margin −148.2%'23FY2024 revenue: $26.4MFY2024 net income: −$62.0M · Net margin −235.1%'24FY2025 revenue: $18.7MFY2025 net income: −$64.8M · Net margin −347.0%'25−100%−50%0%50%FY2021 net margin: −77.8%FY2022 net margin: −37.8%FY2023 net margin: −148.2% (off the scale, which stops at −100.0%)FY2024 net margin: −235.1% (off the scale, which stops at −100.0%)FY2025 net margin: −347.0% (off the scale, which stops at −100.0%)
Omniab Inc annual financial statements
FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$34.7M$59.1M$34.2M$26.4M$18.7M
Growth (year over year)—+70.0%−42.2%−22.8%−29.3%
Operating income−$35.6M−$26.6M−$69.4M−$74.5M−$69.0M
Operating margin−102.5%−45.1%−203.2%−282.3%−369.5%
Net income−$27.0M−$22.3M−$50.6M−$62.0M−$64.8M
Net margin−77.8%−37.8%−148.2%−235.1%−347.0%
EPS (diluted)−$0.33−$0.26−$0.51−$0.61−$0.57
Balance sheet
Cash and equivalents$0$33.4M$16.4M$27.6M$25.5M
Total assets$304.5M$421.2M$375.2M$325.6M$300.9M
Total liabilities$70.2M$79.8M$60.6M$37.9M$33.9M
Shareholders' equity$234.3M$341.4M$314.6M$287.6M$267.0M
Cash flow
Operating cash flow−$5.67M−$3.59M$2.35M−$39.7M−$36.5M
Capital expenditure$4.07M$17.2M$1.64M$1.88M$565.0K
Free cash flow−$9.74M−$20.8M$703.0K−$41.5M−$37.0M

From Omniab Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Omniab Inc

Headquarters
Emeryville, California From SEC filings, Oct 2026

Recent News (2)

More Health Care stocks

Browse all companies →